vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $18.6M, roughly 1.6× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -438.1%, a 503.9% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 220.4%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 268.5%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
DOMH vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $18.6M |
| Net Profit | $-131.8M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | 56.3% |
| Net Margin | -438.1% | 65.7% |
| Revenue YoY | 220.4% | 1808.5% |
| Net Profit YoY | -12426.2% | 376.5% |
| EPS (diluted) | $-6.94 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $18.6M | ||
| Q3 25 | $50.8M | $334.0K | ||
| Q2 25 | $34.1M | $1.4M | ||
| Q1 25 | $8.1M | $257.0K | ||
| Q4 24 | $9.4M | $977.0K | ||
| Q3 24 | $4.0M | $660.0K | ||
| Q2 24 | $6.2M | $736.0K | ||
| Q1 24 | $1.4M | $1.4M |
| Q4 25 | $-131.8M | $12.3M | ||
| Q3 25 | $125.2M | $-8.6M | ||
| Q2 25 | $16.6M | $-6.9M | ||
| Q1 25 | $-32.5M | $-5.4M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-4.2M | $-2.8M | ||
| Q2 24 | $-6.1M | $-14.5M | ||
| Q1 24 | $-5.4M | $411.0K |
| Q4 25 | -8.9% | 56.3% | ||
| Q3 25 | -3.1% | -2516.5% | ||
| Q2 25 | -57.0% | -701.0% | ||
| Q1 25 | -394.6% | -3350.2% | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | -79.1% | -1563.6% | ||
| Q2 24 | -44.3% | -1255.0% | ||
| Q1 24 | -205.2% | -692.5% |
| Q4 25 | -438.1% | 65.7% | ||
| Q3 25 | 246.4% | -2572.2% | ||
| Q2 25 | 48.7% | -504.8% | ||
| Q1 25 | -400.5% | -2097.7% | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | -104.2% | -425.5% | ||
| Q2 24 | -99.1% | -1964.4% | ||
| Q1 24 | -398.0% | 29.9% |
| Q4 25 | $-6.94 | $0.25 | ||
| Q3 25 | $7.27 | $-0.17 | ||
| Q2 25 | $1.12 | $-0.14 | ||
| Q1 25 | $-3.02 | $-0.11 | ||
| Q4 24 | $0.21 | — | ||
| Q3 24 | $-0.67 | $-0.06 | ||
| Q2 24 | $-1.01 | $-0.30 | ||
| Q1 24 | $-0.91 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $49.4M |
| Total Assets | $112.9M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $40.0M | ||
| Q3 25 | $176.2M | $37.9M | ||
| Q2 25 | $28.2M | $44.8M | ||
| Q1 25 | $18.9M | $40.6M | ||
| Q4 24 | $8.2M | $59.3M | ||
| Q3 24 | $7.2M | $68.8M | ||
| Q2 24 | $12.1M | $73.0M | ||
| Q1 24 | $7.1M | $80.2M |
| Q4 25 | $69.4M | $49.4M | ||
| Q3 25 | $210.2M | $36.4M | ||
| Q2 25 | $88.6M | $44.5M | ||
| Q1 25 | $42.4M | $50.5M | ||
| Q4 24 | $39.9M | $55.1M | ||
| Q3 24 | $38.3M | $58.5M | ||
| Q2 24 | $42.4M | $60.4M | ||
| Q1 24 | $47.7M | $74.1M |
| Q4 25 | $112.9M | $59.0M | ||
| Q3 25 | $223.4M | $51.1M | ||
| Q2 25 | $109.3M | $60.7M | ||
| Q1 25 | $52.3M | $67.9M | ||
| Q4 24 | $47.1M | $90.6M | ||
| Q3 24 | $43.4M | $99.0M | ||
| Q2 24 | $49.1M | $107.8M | ||
| Q1 24 | $52.2M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $18.4M | ||
| Q3 25 | $-4.9M | $-8.7M | ||
| Q2 25 | $-353.0K | $-7.5M | ||
| Q1 25 | $1.2M | $-7.5M | ||
| Q4 24 | $-16.7M | $-24.0M | ||
| Q3 24 | $-4.7M | $765.0K | ||
| Q2 24 | $1.4M | $-10.9M | ||
| Q1 24 | $-8.6M | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
